ATE428437T1 - Dc-sign blockern und deren verwendung zur vorbeugung oder behandlung von viraleninfektionen - Google Patents

Dc-sign blockern und deren verwendung zur vorbeugung oder behandlung von viraleninfektionen

Info

Publication number
ATE428437T1
ATE428437T1 AT03810566T AT03810566T ATE428437T1 AT E428437 T1 ATE428437 T1 AT E428437T1 AT 03810566 T AT03810566 T AT 03810566T AT 03810566 T AT03810566 T AT 03810566T AT E428437 T1 ATE428437 T1 AT E428437T1
Authority
AT
Austria
Prior art keywords
viral infections
sign
compositions
sign receptor
mammal
Prior art date
Application number
AT03810566T
Other languages
English (en)
Inventor
Ali Amara
Fernando Arenzana-Seisdedos
Philippe Despres
Jean-Louis Virelizier
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst Nat Sante Rech Med filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE428437T1 publication Critical patent/ATE428437T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03810566T 2002-11-05 2003-11-05 Dc-sign blockern und deren verwendung zur vorbeugung oder behandlung von viraleninfektionen ATE428437T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42358202P 2002-11-05 2002-11-05
US42524602P 2002-11-12 2002-11-12
PCT/IB2003/005569 WO2004041299A1 (en) 2002-11-05 2003-11-05 Dc-sign blockers and their use for preventing or treating viral infections.

Publications (1)

Publication Number Publication Date
ATE428437T1 true ATE428437T1 (de) 2009-05-15

Family

ID=32314490

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03810566T ATE428437T1 (de) 2002-11-05 2003-11-05 Dc-sign blockern und deren verwendung zur vorbeugung oder behandlung von viraleninfektionen

Country Status (7)

Country Link
US (2) US20060134100A1 (de)
EP (1) EP1562628B1 (de)
AT (1) ATE428437T1 (de)
AU (1) AU2003301804A1 (de)
BR (1) BR0315975A (de)
DE (1) DE60327237D1 (de)
WO (1) WO2004041299A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427469B2 (en) * 2002-11-05 2008-09-23 Institut Pasteur Method of treating cytomegalovirus with DC-SIGN blockers
BR0315975A (pt) * 2002-11-05 2005-09-20 Pasteur Institut Usos de uma quantidade de um modulador e de um bloqueador de dc-sign, composição farmacêutica, métodos para identificar um modulador e um bloqueador de dc-sign, bloqueador de dc-sign isolado, e, método para alvejar uma molécula objeto a uma célula que expressa um receptore de dc-sign
TWI333959B (en) * 2005-08-31 2010-12-01 Academia Sinica Methods and reagents for the analysis and purification of polysaccharides
US7943134B2 (en) * 2005-08-31 2011-05-17 Academia Sinica Compositions and methods for identifying response targets and treating flavivirus infection responses
JP2009509970A (ja) * 2005-09-22 2009-03-12 プロサイ インコーポレイテッド 酵母突然変異体において産生されるグリコシル化ポリペプチドおよびその使用方法
AT503387B1 (de) * 2006-03-27 2008-05-15 Univ Wien Pharmazeutische zusammensetzung zur vorbeugung von infektionen
US8291907B2 (en) * 2007-10-12 2012-10-23 David Charles Kuhlmann Apparatus for supporting the head of a person lying prone or on a side
EP2478359A4 (de) * 2009-09-14 2013-03-20 Univ Rockefeller Verfahren zur identifikation entzündungshemmender verbindungen
CN104459146B (zh) * 2013-09-16 2016-06-22 大连医科大学 Dc-signr的一种新用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1991005876A1 (en) 1989-10-20 1991-05-02 Children's Biomedical Research Institute Human cytomegalovirus-specific monoclonal antibody cocktail
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US4983202A (en) * 1990-02-27 1991-01-08 Libbey-Owens-Ford Co. Glass sheet heating furnace and method of using
GB9008223D0 (en) * 1990-04-11 1990-06-13 Royal Free Hosp School Med Improvements relating to the detection of viruses
DK1471142T3 (da) * 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
MX9204131A (es) * 1991-07-16 1993-04-01 Bristol Myers Squibb Co Proteina receptora de gp120.
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5667988A (en) * 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
DE4402273C2 (de) * 1994-01-27 1995-11-23 Voith Gmbh J M Papiermaschine zur Herstellung mehrlagiger Papierbahnen
US5516637A (en) * 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
ATE227584T1 (de) * 1995-05-24 2002-11-15 Hawaii Biotech Group Untereinheitsimpfstoff gegen flavivirus infektion
EP1046651A1 (de) 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Zusammensetzungen und Verfahren zur Modulierung des interaktion zwischen dendritischer und T-zellen
US6391567B1 (en) 2000-03-02 2002-05-21 New York University Identifying compounds inhibiting DC-sign facilitation of HIV into cells
US8318173B2 (en) * 2001-04-05 2012-11-27 The John Hopkins University Chimeric vaccines
US7427469B2 (en) * 2002-11-05 2008-09-23 Institut Pasteur Method of treating cytomegalovirus with DC-SIGN blockers
BR0315975A (pt) * 2002-11-05 2005-09-20 Pasteur Institut Usos de uma quantidade de um modulador e de um bloqueador de dc-sign, composição farmacêutica, métodos para identificar um modulador e um bloqueador de dc-sign, bloqueador de dc-sign isolado, e, método para alvejar uma molécula objeto a uma célula que expressa um receptore de dc-sign

Also Published As

Publication number Publication date
AU2003301804A1 (en) 2004-06-07
BR0315975A (pt) 2005-09-20
EP1562628B1 (de) 2009-04-15
US7419789B2 (en) 2008-09-02
EP1562628A1 (de) 2005-08-17
US20060134100A1 (en) 2006-06-22
DE60327237D1 (de) 2009-05-28
WO2004041299A1 (en) 2004-05-21
US20040197330A1 (en) 2004-10-07
AU2003301804A8 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
DE602006011910D1 (de) Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
EA200700212A1 (ru) Многовалентные vla-4 антагонисты, содержащие полимерные фрагменты
TW200738657A (en) Thiazole compounds and methods of use
MX2012004084A (es) Anticuerpos siglec-15 para tratar enfermedad relacionada con perdida osea.
EA200800763A1 (ru) Терапевтические композиции, содержащие гиалуроновую кислоту и терапевтические антитела, а также способы лечения
EA200970250A1 (ru) Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения
EA201691260A1 (ru) ВАРИАНТЫ, ПРОИСХОДЯЩИЕ ИЗ ActRIIB, И ИХ ПРИМЕНЕНИЕ
DE69729125D1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
NO20055907L (no) Fremgangsmate for behandling av en angstforstyrrelse
DE602005008013D1 (de) Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie
ATE473728T1 (de) Verwendung von fluoreszierenden perlylenverbindungen zur behandlung menschlicher haare
ATE428437T1 (de) Dc-sign blockern und deren verwendung zur vorbeugung oder behandlung von viraleninfektionen
DE60333901D1 (de) Verfahren zur reduzierung der angiogenese
ATE292677T1 (de) Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
DE602005018366D1 (de) Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen
ATE473277T1 (de) Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten
ATE521631T1 (de) Verwendung von aimp2dx2 zur diagnose und behandlung von krebs
EA200701584A1 (ru) Органические соединения, применяемые для лечения болезни альцгеймера, их применение и способ получения
EA200300442A1 (ru) Способы и композиции для лечения воспалительных заболеваний
DE602004021933D1 (de) 4-brom-5-(2-chlor-benzoylamino)-1h-pyrazol-3-carbonsäure(phenyl)amid-derivate und verwandte verbindungen als bradykinin b1 receptor antagonisten zur behandlung von entzündlichen erkrankungen
MX2021008081A (es) Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties